Autopsy report · NCT02159690

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

“loss of funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Kenneth Pienta, MD

Sponsor type

University, hospital or other

Conditions

Prostate Cancer; Localized Prostate Cancer

Interventions

Enzalutamide; Abiraterone acetate; Prednisone; Dutasteride; Degarelix

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Evaluating Autologous Stromal Vascular Fraction in Subjects with Vocal Fold Scar
  “Funding loss” (97% match in meaning)
• Meru Health Program to Treat Depression in Primary Care
  “Loss of grant funding.” (89% match in meaning)
• The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC
  “Loss of external funding” (87% match in meaning)
• Mepolizumab for Eosinophilic Fasciitis
  “Funding lost from Sponsor.” (86% match in meaning)
• Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
  “Low accrual/Loss of funding” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.